The inhibitors of the immune checkpoint proteins programmed cell death ligand-1 (PD-L1), programmed cell death-1 (PD-1), and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) are therapeutic agents used to treat NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.